한글목차

아시아태평양의 급성기 의료 신드로믹 검사 시장 규모는 2023년에 7억 8,000만 달러로 평가되며, 2023-2033년 10.97%의 CAGR로 성장하며, 2033년에는 22억 달러에 달할 것으로 예측되고 있습니다.

이 시장의 성장은 감염증의 발생률 증가, 팬데믹 발생, 지구 온난화에 의해 악화된 다양한 지역에서 새로운 감염증의 식별에 의해 감염증의 조기 발견에 대한 요구가 높아지고 있는 것에 기인하고 있습니다.

아시아태평양(APAC) 지역의 급성기 의료 신드로믹 검사 시장은 강력한 성장세를 보이고 있으며, 이 지역의 의료 환경에서 점점 더 많은 관심을 받고 있습니다. 증후군 검사는 급성 질환을 신속하게 진단하고 관리하며, 발병 및 응급상황에 적시에 대응하는 데 있으며, 매우 중요한 역할을 합니다. 이러한 시장 확대는 감염성 질환의 발병률 증가, 조기 진단의 중요성에 대한 인식 증가, 진단 기술의 발전 등의 요인에 의해 이루어지고 있습니다.

최근 아시아태평양에서는 의료 인프라에 대한 대규모 투자와 혁신적인 진단 솔루션 도입이 활발히 진행되고 있습니다. 이러한 투자는 응급의료 및 중증 의료 현장에서 보다 신속하고 정확한 진단을 가능하게 하는 급성기 증후군 검사 시장을 강화하고 있습니다. 또한 현재 진행 중인 COVID-19 팬데믹은 공중보건 대응에 있으며, 증후군 검사의 중요한 역할을 강조하고 있으며, 아시아태평양 전체에서 이러한 검사 솔루션에 대한 수요를 더욱 촉진하고 있습니다.

아시아태평양의 급성기 의료 신드로믹 검사 시장에 대해 조사했으며, 시장의 개요와 최종사용자별, 국가별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.

목차

주요 요약

제1장 시장

• 시장 범위
• 조사 방법

제2장 시장 개요

• 개요
• 급성기 치료 증후군 검사 워크플로우 분석
• 시장 발자국과 성장 가능성
• 향후 가능성

제3장 업계 인사이트

• 이해관계자의 시점(N=20)
• 급성기 의료 신드로믹 검사 시장의 법적 및 규제 프레임워크
• 제품 벤치마킹

제4장 시장 역학

• 개요
• 영향 분석
• 시장 촉진요인
• 시장이 해결해야 할 과제
• 시장의 기회

제5장 급성기 의료 신드로믹 검사 시장(지역별), 2022-2033년

• 개요
• 아시아태평양
  • 아시아태평양의 급성기 의료 신드로믹 검사 시장, 최종사용자별
  • 아시아태평양의 급성기 의료 신드로믹 검사 시장, 국가별

제6장 기업 개요

• Acute Care Syndromic Testing Ecosystem Active Players
• Seegene Inc.
• SpeeDx

영문목차

“The Asia-Pacific Acute Care Syndromic Testing Market Expected to Reach $2.20 Billion by 2033.”

Introduction to Asia-Pacific Acute Care Syndromic Testing Market

The Asia-Pacific acute care syndromic testing market was valued at $0.78 billion in 2023 and is expected to reach $2.20 billion by 2033, growing at a CAGR of 10.97% between 2023 and 2033. The growth of the market can be attributed to the rising need for early detection of infectious diseases, driven by the growing incidence of such diseases, the occurrence of pandemics, and the identification of new infectious diseases in various regions, exacerbated by global warming.

Market Introduction

The Asia-Pacific (APAC) acute care syndromic testing market is experiencing robust growth and increasing prominence in the region's healthcare landscape. Syndromic testing plays a pivotal role in rapidly diagnosing and managing acute illnesses, offering a timely response to outbreaks and emergencies. This market's expansion is driven by factors such as the rising incidence of infectious diseases, growing awareness of the importance of early diagnosis, and advancements in diagnostic technologies.

In recent years, APAC has witnessed significant investments in healthcare infrastructure and the adoption of innovative diagnostic solutions. These investments have bolstered the acute care syndromic testing market, enabling quicker and more accurate diagnoses in emergency and critical care settings. Furthermore, the ongoing COVID-19 pandemic has underscored the critical role of syndromic testing in public health response, further fueling the demand for such testing solutions across the APAC region.

Market Segmentation:

Segmentation 1: by End User

• Hospitals
• Clinical and Diagnostic Laboratories
• Research and Academic Institutions
• Other End Users

Segmentation 2: by Country

• Japan
• India
• China
• South Korea
• Australia
• Rest-of-Asia-Pacific

How Can This Report Add Value to an Organization?

Growth/Marketing Strategy: Synergistic activities, product launches, and approvals accounted for the maximum number of key developments.

Competitive Strategy: The APAC acute care syndromic testing market has numerous startups paving their way into manufacturing kits, panels, assays, and instruments and entering the market. Key players in the APAC acute care syndromic testing market analyzed and profiled in the study involve established players that offer various kinds of disease-specific panels and multiplex instruments.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

Table of Contents

Executive Summary

1. Markets

• 1.1. Market Scope
  • 1.1.1. Key Questions Answered in the Report
• 1.2. Research Methodology
  • 1.2.1. Acute Care Syndromic Testing Market: Research Methodology
  • 1.2.2. Data Sources
    • 1.2.2.1. Primary Data Sources
    • 1.2.2.2. Secondary Data Sources
  • 1.2.3. Market Estimation Model
  • 1.2.4. Criteria for Company Profiling

2. Market Overview

• 2.1. Overview
• 2.2. Acute Care Syndromic Testing Workflow Analysis
• 2.3. Market Footprint and Growth Potential
• 2.4. Future Potential

3. Industry Insight

• 3.1. Stakeholder's Perspective (N=20)
  • 3.1.1. Physician's Perception
  • 3.1.2. Payor's Perception
  • 3.1.3. Investor's Perception
• 3.2. Legal and Regulatory Framework of the Acute Care Syndromic Testing Market
  • 3.2.1. Regulatory Framework in Asia-Pacific
    • 3.2.1.1. Japan
    • 3.2.1.2. China
    • 3.2.1.3. India
    • 3.2.1.4. South Korea
    • 3.2.1.5. Australia
• 3.3. Product Benchmarking

4. Market Dynamics

• 4.1. Overview
• 4.2. Impact Analysis
• 4.3. Market Drivers
  • 4.3.1. Faster Results Acquired with Syndromic Tests
  • 4.3.2. Increasing Incidence of Infectious Diseases
  • 4.3.3. Overall Reduced Cost of Care Due to Early Diagnosis with Syndromic Testing
  • 4.3.4. Reduced Severe Adverse Effects from Pathogens
• 4.4. Market Challenges
  • 4.4.1. Need for Better Policies with Respect to Acute Care Syndromic Test Reimbursement
  • 4.4.2. Lack of High-Complexity Testing Centres
• 4.5. Market Opportunities
  • 4.5.1. Quick Access to Treatment and Reduced Use of Antibiotics
  • 4.5.2. High Number of Synergistic Activities and Mergers and Acquisitions (M&A) Over the Past Years

5. Acute Care Syndromic Testing Market (By Region), 2022-2033

• 5.1. Overview
• 5.2. Asia-Pacific
  • 5.2.1. Asia-Pacific Acute Care Syndromic Testing Market, By End User
  • 5.2.2. Asia-Pacific Acute Care Syndromic Testing Market, By Country
    • 5.2.2.1. China
    • 5.2.2.2. Japan
    • 5.2.2.3. India
    • 5.2.2.4. Australia
    • 5.2.2.5. South Korea
    • 5.2.2.6. Rest-of-Asia-Pacific

6. Company Profiles

• 6.1. Overview
• 6.2. Acute Care Syndromic Testing Ecosystem Active Players
• 6.3. Seegene Inc.
  • 6.3.1. Company Overview
  • 6.3.2. Role of Seegene, Inc. in the Acute Care Syndromic Testing Market
  • 6.3.3. Financials
  • 6.3.4. Recent Developments
    • 6.3.4.1. Corporate Strategies
    • 6.3.4.2. Business Strategies
  • 6.3.5. Analyst Perspective
• 6.4. SpeeDx
  • 6.4.1. Company Overview
  • 6.4.2. Role of SpeeDX in the Acute Care Syndromic Testing Market
  • 6.4.3. Analyst Perspective